Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4737125 | 0.84 | KDM4E (0.56) | KDM4EALDH1A1HPGDALOX15MAPT | |
| SCHEMBL2704348 | 0.81 | ALDH1A1 (0.55) | KDM4EALDH1A1HPGDALOX15MAPT | |
| SCHEMBL31483916 | 0.81 | KDM4E (0.57) | KDM4EALDH1A1HPGDALOX15MAPT | |
| SCHEMBL31184233 | 0.81 | ALDH1A1 (0.55) | KDM4EALDH1A1HPGDALOX15MAPT | |
| SCHEMBL4876987 | 0.81 | KDM4E (0.57) | KDM4EALDH1A1HPGDALOX15MAPT | |
| SCHEMBL4872497 | 0.80 | MAPT (0.48) | KDM4EALDH1A1HPGDALOX15MAPT | |
| SCHEMBL2900687 | 0.79 | KMT2A (0.65) | KDM4EALDH1A1MAPTPOLBSMN1; SMN2 | |
| SCHEMBL2301745 | 0.79 | KDM4E (0.77) | KDM4EALDH1A1HPGDALOX15MAPT | |
| SCHEMBL8643558 | 0.79 | KDM4E (0.67) | KDM4EALDH1A1HPGDALOX15MAPT | |
| SCHEMBL3227432 | 0.78 | KDM4E (0.71) | KDM4EALDH1A1HPGDALOX15MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1904474-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007008140-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312208-A1 | Pyridine Analogues | P2RY12, P2RY11, P2RY1 | KDM4E 1759/4885ALDH1A1 1274/4885HPGD 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.